Literature DB >> 1356550

Neuroleptic sensitivity in patients with senile dementia of Lewy body type.

I McKeith1, A Fairbairn, R Perry, P Thompson, E Perry.   

Abstract

OBJECTIVE: To determine the outcome of administration of neuroleptics to patients with senile dementia of Lewy body type confirmed at necropsy.
DESIGN: Retrospective analysis of clinical notes blind to neuropathological diagnosis.
SETTING: Specialist psychogeriatric assessment units referring cases for necropsy to a teaching hospital neuropathology service. PATIENTS: 41 elderly patients with diagnosis of either Alzheimer type dementia (n = 21) or Lewy body type dementia (n = 20) confirmed at necropsy. MAIN OUTCOME MEASURES: Clinical state including extrapyramidal features before and after neuroleptic treatment and survival analysis of patients showing severe neuroleptic sensitivity compared with the remainder in the group.
RESULTS: 16 (80%) patients with Lewy body type dementia received neuroleptics, 13 (81%) of whom reacted adversely; in seven (54%) the reactions were severe. Survival analysis showed an increased mortality in the year after presentation to psychiatric services compared with patients with mild or no neuroleptic sensitivity (hazard ratio 2.70 (95% confidence interval 2.50-8.99); (chi 2 = 2.68, p = 0.05). By contrast, only one (7%) of 14 patients with Alzheimer type dementia given neuroleptics showed severe neuroleptic sensitivity.
CONCLUSIONS: Severe, and often fatal, neuroleptic sensitivity may occur in elderly patients with confusion, dementia, or behavioural disturbance. Its occurrence may indicate senile dementia of Lewy body type and this feature has been included in clinical diagnostic criteria for this type of dementia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356550      PMCID: PMC1882909          DOI: 10.1136/bmj.305.6855.673

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  6 in total

1.  Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease.

Authors:  E K Perry; I McKeith; P Thompson; E Marshall; J Kerwin; S Jabeen; J A Edwardson; P Ince; G Blessed; D Irving
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.

Authors:  G Lennox; J Lowe; M Landon; E J Byrne; R J Mayer; R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

3.  Patterns of neuroleptic use among the institutionalised elderly.

Authors:  C J Gilleard; K Morgan; B E Wade
Journal:  Acta Psychiatr Scand       Date:  1983-12       Impact factor: 6.392

4.  Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly.

Authors:  R H Perry; D Irving; G Blessed; A Fairbairn; E K Perry
Journal:  J Neurol Sci       Date:  1990-02       Impact factor: 3.181

5.  The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.

Authors:  L Hansen; D Salmon; D Galasko; E Masliah; R Katzman; R DeTeresa; L Thal; M M Pay; R Hofstetter; M Klauber
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

6.  Behavioral problems among patients in skilled nursing facilities.

Authors:  J G Zimmer; N Watson; A Treat
Journal:  Am J Public Health       Date:  1984-10       Impact factor: 9.308

  6 in total
  97 in total

1.  Treating behavioural and psychological signs in Alzheimer's disease.

Authors:  C Ballard; J O'Brien
Journal:  BMJ       Date:  1999-07-17

Review 2.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

3.  Optimising management of delirium. Placebo controlled trials of pharmacological treatments are needed.

Authors:  C J Ryan
Journal:  BMJ       Date:  2001-06-30

4.  Meige's syndrome in dementia with Lewy bodies.

Authors:  Naji Tabet; Saraswathy Sivaloganathan
Journal:  J R Soc Med       Date:  2002-04       Impact factor: 5.344

Review 5.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

Review 7.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

8.  Neuroleptic sensitivity in dementia with cortical Lewy bodies.

Authors:  E J Byrne; A Burns; J Waite
Journal:  BMJ       Date:  1992-11-07

9.  Dementia with lewy bodies: diagnosis and management for primary care providers.

Authors:  Melanie Zupancic; Aman Mahajan; Kamna Handa
Journal:  Prim Care Companion CNS Disord       Date:  2011

10.  A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies.

Authors:  M Yoshita; J Taki; M Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.